Pharma Journalist

6th Age-Related Disease Therapeutics Summit
2024-06-11 - 2024-06-13 | Hyatt Centric Fisherman’s Wharf, 555 North Point Street, San Francsico, CA, 94133, United States
The 6th Age-Related Disease Therapeutics Summit is returning to San Francisco in June, with 60+ participants including Eli Lilly, Takeda, and Turn Biosciences to dive deep into breakthroughs in cellular programming, senolytic pathways, and epigenetic effects. Explore biomarkers, navigate regulations, and foster collaborations for pipeline support and commercialization.
This is your definitive age-related disease therapeutics forum to gain unparalleled competitive intelligence, scientific advancements and form meaningful partnerships to solve humankind’s fundamental problem.

4th Next Generation Gene Therapy Vectors Summit
2024-06-12 - 2024-06-14 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14, Boston)
As a recent whitepaper by the Alliance for Regenerative Medicine cites capsid engineering and disruptive delivery platforms as key emerging technologies in the CGT space, drug developers are heavily investing in finding and optimizing the safety, efficacy, and predictability of delivery platforms.
This is 2024’s only meeting covering the latest advances and innovations in vector development for gene therapies, uniting 90+ R&D and business development leaders to advance cutting-edge delivery platforms into the clinic. Data-driven talks, expert panels, and interactive group discussions led by 25+ industry experts will provide you with the ‘latest and greatest’ in both disruptive viral and non-viral vectors.
Join us to gain actionable insights in how to enable targeted gene delivery, reduce immunogenicity & toxicity, enhance downstream manufacturability, expand packaging capabilities, and secure funding and investment for your own vector platform.
Want to learn more? Check out the event guide here https://ter.li/nnkbb3

World CDx Regulatory Affairs & Policy Summit
2024-06-19 - 2024-06-20 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The highly anticipated World CDx Regulatory Affairs & Policy Summit, is set to debut in Boston from June 19-20, 2024.
From tackling the complexities of LDT regulation and navigating the IVDR maze to understanding reimbursement dynamics, this groundbreaking meeting promises to provide clarity and harmonization in the realm of CDx regulation. Attendance is FREE for drug developers and academics, join us to maintain your clinical momentum, streamline submissions, overcome regulatory bottlenecks, and improve patient access to companion diagnostics.
World Class speakers you have the opportunity to learn from:

Vihanga Pahalawatta, Director – Regulatory Affairs Companion Diagnostics, AbbVie
Andrea Renninger, Senior Director – CDx Regulatory Affairs, Daiichi Sankyo
Claudia Dollins, Vice President – Global Regulatory Affairs, GSK
Debra Rasmussen, Senior Director – Global Regulatory Affairs, Johnson & Johnson
Dun Liang – Executive Director, Regulatory Affairs, CDx, Loxo@Lilly
Siddhartha Mathur – Executive Director – Regulatory Affairs, Merck
Qing Li, Director – Pathology, clinical development, Oncology, Moderna
Jai Pandey, Global Head – Device Regulatory for In Vitro Diagnostics & Companion Diagnostics, Digital Health, Sanofi

This summit is poised to bring together key stakeholders, including Directors, VPs, and SVPs in Regulation, Policy, Reimbursement, Digital Health, and Companion Diagnostics from leading companies as well as regulatory experts, payers, and developers to bridge the gap with clinical practice and ease regulatory pressures. Download the brochure or secure your free place now!

Cell & Gene Therapy Pricing & Reimbursement Summit
2024-06-25 - 2024-06-27 | Marriott Washington Capitol Hill, 175 L Street NE, WA, 20002, United States
Cell and gene therapies are revolutionizing healthcare, offering promising solutions from curative treatments to long-term remission rates. As these treatments enter the market, ensuring fair access while addressing coverage and payment complexities becomes paramount.
Introducing the inaugural Cell & Gene Therapy Pricing & Reimbursement Summit. Biotech, pharma, physicians, healthcare providers, and regulatory and government agencies will unite to address key issues such as the impact of regulatory acts, implementing pricing models, and collaborating on enhanced reimbursement strategies, aiming to expedite the availability of these advanced therapies to patients.
With the recent approval of Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia by bluebird bio; significant strides in healthcare have been made, offering groundbreaking treatments with transformative potential, yet presenting substantial cost challenges. The Inflation Reduction Act and new Cell and Gene Therapy (CGT) Access Model aim to address these cost concerns by proposing innovative pricing models and reimbursement strategies to ensure affordability and widespread access to these life-changing therapies.
Join us this June to discuss the impacts of this legislation and together, we will optimize patient access and propel the success of commercial cell and gene therapy launches.
See the full agenda here: https://ter.li/d1rn7b

2nd mRNA Quality Control & Compliance Summit
2024-06-25 - 2024-06-27 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Regulatory guidelines and existing protocols to govern aspects of mRNA quality during development and manufacturing are still evolving, creating a lack of clarity and consensus amongst the mRNA community.
Without a clear path forward, drug developers risk comprising product quality, safety and efficacy, and so the 2nd mRNA Quality Control & Compliance Summit is back to Boston this June as the sole industry-centred forum dedicated to showcasing data and discussions on mRNA compliance and optimized documentation, ensuring streamlined approval for mRNA therapeutics and vaccines!
Reuniting industry experts in quality control, quality assurance, analytical development, and CMC, this forum aims to navigate regulatory guidelines and identify tangible best practices towards optimized documentation, discuss verification processes for platform methods and review method validation used to evaluate critical vaccine qualities, all towards safeguarding faster mRNA drug approvals in line with regulatory expectations.
Download the free brochure or book your place now, early birds are still available!

3rd In Vivo Cell Engineering & Gene Editing Summit
2024-07-09 - 2024-07-11 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Welcome to the Future of Cell & Gene Therapy
The 3rd In Vivo Cell Engineering & Gene Editing Summit is an annual event uniting C-level in vivo experts to facilitate safe and targeted in vivo delivery of payloads while providing clarity in regulations and appropriate models to advance the next frontier of in vivo editing from research to clinic.
Explore the full agenda – https://ter.li/snxcxi
As promising pre-clinical and proof of concept results continue to emerge, the ‘dream’ of in vivo cell engineering and gene editing is rapidly becoming a reality as numerous companies push towards the clinic.
Join us this July to network with and gain invaluable knowledge from our world-class speaker faculty from Capstan Therapeutics, Editas Medicine, NanoCell Therapeutics, Carisma Therapeutics, Sanofi, and more, offering exclusive insights into their strategies for staying ahead of the curve and shaping the future of cell and gene therapy in the years ahead.
Key Highlights:

Exploring data-driven case studies to outline decision making when selecting viral versus non-viral vectors
Clarifying regulatory expectations for this novel therapeutic approach to map out the future of your pipeline
Benchmarking appropriate preclinical models to support translation to gain valuable data needed by regulatory bodies
Outlining the considerations when scaling up towards the clinic to equip you with the tools to tackle bottlenecks
Emphasizing target specificity and the mitigation off-site toxicities to ensure safety is front of mind in development

Register now for the best savings – https://ter.li/ssnrpz
#InVivoCellEngineeringandGeneEditingSummit

4th mRNA-Based Therapeutics Summit
2024-07-29 - 2024-07-31 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to Commercialization by Ensuring Targeted Delivery, Durability & Tolerable Immunogenicity Across All Disease Indications
As mRNA developments continue to dominate industry news, ranging from winning the Nobel Prize to new clinical candidates, positive Phase I readouts and approvals, the industry is set to reunite in Boston this July for the 4th mRNA-Based Therapeutics Summit.
Hear the latest unseen data from proof-of-concept studies, platform development, clinical updates and regulatory insights as 65+ world-class speakers take to the stage. With expert-led sessions by the likes of the FDA, EMA, Moderna, BioNTech and Sanofi, this year’s 4-track agenda will provide unmissable scientific and strategic insights into the biggest challenges faced in discovery, translation, clinical development, and CMC.

Dates: July 29-31, 2024
Location: Westin Boston Seaport District, Boston, MA
Event Program: https://ter.li/fezohk

Join the Next Generation mRNA Delivery or Regulatory Affairs Strategy focus days, exchange business cards in Speed Networking, quiz your peers in the Scientific Poster Session and have your voice heard during the Roundtable Discussions to maximize your experience at this year’s summit.
Download the agenda here: https://ter.li/fezohk
Register your place here (and take advantage of group discounts of up to 20% when sending your team of three or more!): https://ter.li/6vnq38

5th Gamma Delta T Cell Therapies Summit
2024-07-29 - 2024-07-31 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 5th Gamma Delta T Cell Therapies Summit will bring together experts from big pharma, biotech and academia to delve into the details of gamma delta biology and its various subsets to offer the audience a well-rounded overview of the landscape currently and the steps needed for it to move forward.
Find out more here: https://ter.li/yryaj1

With a world-class speaker faculty sharing the latest insights in the field, this meeting continues to be the one-stop shop to accelerate your gamma delta T therapies! Hear from IN8Bio, Adicet Bio, Acepodia, Takeda, Luminary Therapeutics, LAVA Therapeutics, OneChain Therapeutics and many more!
As the ONLY industry gamma delta T cell-specific meeting running this year, these three days will expedite the translation of your vd1/vd2 pipelines from bench to bedside, fostering prompt progress in the field. Take this opportunity to upskill your cross-functional team across discovery, translation, clinical development, CMC and manufacturing to successfully translate basic research into your clinical strategy to support your IND submission.
Find out more here: https://ter.li/yryaj1

2nd RNA Assay Development Screening Summit
2024-08-20 - 2024-08-22 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
There has been many exciting investments and advancements in the field, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and screening methods for understanding the RNA target structure as well as the mechanism of action of the small molecule drugs.
Hence, this August the 2nd RNA Assay Development & Screening Summit returns to Boston as the first and only industry dedicated event on developing sensitive, and reproducible assay and screening methods. With 70% brand new speaker faculty from key stakeholder companies as well as new companies entering the field, including the likes of AstraZeneca, Arrakis Therapeutics, Molecure, Wayfinder Biosciences, Biogen and more, access the latest strategies for developing reproducible and sensitive assay and screening methods.
Download the free brochure or book your place now, early birds are still available!

5th Gene Therapy Immunogenicity Summit
2024-08-20 - 2024-08-22 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Optimize Safety & De-Risk Efficacy of Viral Vector-Based Gene Therapies
The success of gene therapy hinges on overcoming the immunogenicity challenges of viral vectors. With more viral vector-based gene therapies progressing through the pipeline, we need to seek solutions to this critical bottleneck ‘here and now’.
The 5th Gene Therapy Immunogenicity Summit is returning to Boston this August, bringing together 100+ immunogenicity experts responsible for predicting, measuring, and mitigating immune response. Join your colleagues as they share their learnings and gain key insights on:

Effective approaches to promote AAV safety whilst maintaining efficacy
Preventing the bottlenecks of the potential slowdown of gene therapy development

Access specific, case-study-led examples across immunogenicity and ask the big-hitting immunology questions to your peers actively working in the space to make clinically safe and effective gene therapies a reality.

Predicting and mitigating against complement activation and other toxicity issues with Ask Bio, Takeda, and Novartis
Validating novel Immunoassays, bioanalytical and biodistribution technology with Astellas Gene Therapies and Boehringer Ingelheim
Understanding possible risks around exacerbation of both the innate and adaptive immune response with Roche and Tenaya Therapeutics
Exploring the practicalities of AAV redosing through an immunology lens with the University of Indiana and Adolore Biotherapeutics
Examine the immunogenicity risks specific to gene editing approached as momentum in the field increases with CRISPR and Modalis Therapeutics

2nd ADC Linker & Conjugation Summit
2024-08-20 - 2024-08-22 | W Boston, 100 Stuart Street, Boston, MA, 02116, United States
With Eli Lilly’s acquisition of Mablink and Novartis’ investment in Tagworks, both centering on their innovative linker and conjugation technologies – optimizing linker chemistry and diversifying conjugation technologies to increase stability and selectivity are becoming increasingly more attractive to ADC developers as they strive for a competitive edge over their peers.

As part of the World ADC Series, the 2nd ADC Linker & Conjugation Summit is the only forum exclusively focused on enhancing your linker and conjugation chemistry. With 100+ attendees ranging from boots-on-the-ground scientists working on improving linker & conjugation chemistries daily, through to more senior directors, this conference is the optimal combination of knowledge sharing and networking.
Leave this summit with the confidence to innovate hydrophilic linkers that help prevent aggregation, enhance stability in linkers & conjugations to ensure tumor targeting and hone site-specific conjugations to guarantee homogenous DAR, all to ultimately ensure ADC stability and widen therapeutic index.

3rd Digital Biomarkers & Clinical Measures for Neurology Summit
2024-08-27 - 2024-08-29 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Delivering on the Promise of Precision Medicine with Digital Measures in Neurology
Harnessing More Quantitative, Objective & Less Invasive Measures to Reduce Costs & Improve Neurology Patient Experience
2023 welcomed SV95C as the first ever digital endpoint qualified by a regulatory agency, which means that the floodgates have now opened to the potential of digital biomarkers to transform clinical development in neurology.
From the latest validated research on implementing speech, cognition, and motor tracking measures into clinical development, to navigating the regulatory and commercial landscape, the 3rd Digital Biomarkers & Clinical Measures for Neurology Summit is the ultimate platform to take your digital strategy to the next level.
This August, join 80+ senior industry leaders across digital health, medical affairs, clinical development, and regulatory this year from Biogen, DEEP Measures, Janssen, Alexion Pharmaceuticals, Eisai, Pfizer, Novo Nordisk, Novartis, Boehringer Ingelheim, Takeda, MTP, BMS, Alto Neurosciences, Michael J. Fox Foundation, Cerevel Therapeutics, Regeneron and many more…

3rd Oligonucleotide CMC & Analytical Development Summit
2024-08-27 - 2024-08-29 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Exclusively dedicated to uniting AD, QC, and CMC leaders the 3rd Oligonucleotide CMC & Analytical Development Summit is the only industry-led meeting solving your impurity, regulatory, and cost-efficiency challenges in this rapidly evolving field.
Across the three days, you’ll get the chance to hear from KOLs like Ionis Pharmaceuticals, AstraZeneca, and CAMP4 Therapeutics as the present their data-driven case studies on managing quality, regulatory affairs, and cost-efficient manufacturing.
Deep dive into the major challenges of streamlining analytical tools, process development, and look towards greener chemistries to ensure global uptake of oligonucleotide drugs.
This isn’t just an event, it’s an investment in the future of your teams’ technical capabilities. Bringing together siRNA, mRNA, ASO, oligo and oligo-conjugate developers, this definitive summit fosters comprehensive development, ensuring the resilience and longevity of this rapidly advancing modality.
Join us this August to assess the field, take back actionable insights to your team, and realize the potential of oligonucleotide therapeutics for prevalent diseases and improved market acceptance.
Event highlights:

3 interactive workshops across CMC consideration, oligo-conjugate analytical and detection methods, and how to establish a robust control strategy
18 data-driven case studies from complex oligo synthesis to scale-up and quality control. This is your end-to-end guide for oligo commercialization
100+ industry experts across Analytical Development, CMC and QC teams in attendance, allowing you to connect, benchmark and strive towards common goals together

Expert speakers include:

Angela Tsai, Senior Manager – Collaboration & External Innovation, Sanofi
George Bou-Assaf, Associate Director, Biogen
Huijun Tian, Director, Analytical Development & Quality Control, QurAlis
Isaiah Cedillo, Assistant Director – Manufacturing & Operations, Ionis Pharmaceuticals
Janine Tom, Senior Principal Scientist, Amgen
Satya Kuchimanchi, Senior Vice President, Technical Operations, Chemistry, Manufacturing & Controls, CAMP4 Therapeutics

100+ Industry Experts | 3 Interactive Workshops | 20% Off Group Discounts | Data-Driven Case Studies
To know more visit: https://ter.li/eptndw

3rd Cell Therapy Analytical Development Summit Europe
2024-09-03 - 2024-09-05 | 15Hatfields, Chadwick Court, London, SE1 8DJ, United Kingdom
Bringing together technical experts, the 3rd Cell Therapy Analytical Development Summit Europe, is the definitive summit dedicated to defining and refining analytics to ensure the swift progression of highly efficacious products through IND/IMPD and clinical trials.
Connect with industry-leaders like Achilles Therapeutics, Avobis Bio, Bristol Myers Squibb, Johnson & Johnson, GSK, MHRA, to advance the future development of potent, safe and effective cell therapies!
Join us in London for 3 days of exclusive content focused on providing the exclusive technical insights needed to take your product from characterisation to validation and release!
Access the full session details today.

Wearable Injectors and Connected Devices USA
2024-09-09 - 2024-09-10 | Boston, USA
The Wearable Injectors and Connected Devices event is the only conference that discusses both wearable injectors and connected devices in one event. Over two days, we bring together executives within the pharmaceutical industry to discuss the opportunities and challenges that face on-body devices, and to collaborate on the future of the industry. The event provides and intimate environment to speak with experts and peers to learn from each other’s experiences, and to meet with a variety of solutions providers working to supplement the industry.
The experience:

A collaborative environment for pharma, biotech and device developers to discuss the latest trends and challenges within the wearable injectors and connected device market.
Learn from key industry players about new technologies, strategies and processes for the development of wearable injectors.
Gain insights into the regulatory processes for the approval of wearable injectors and develop a greater understanding of how-to bring devices to market.
Create a dialogue with industry leaders for wearable injectors, and develop a network with the key stake-holders in the market.
Delve into the world of digital health and connectivity for the healthcare sector, and discuss the future of connectivity for wearables.
Examine the importance of usability for at home injectors, and what is needed to make a device appropriate for patient administration.

Why attend:

2 full days of networking opportunities.
16+ sessions with 75% of speakers from big pharma companies
An agenda designed for professionals within the wearable injectors space, focused on the development, implementation and application of wearable injectors and connected devices.
The only conference discussing wearable injectors and connected devices together.

ADC & TRP Pharma & Biotech Partnering Summit
2024-09-09 - 2024-09-10 | Revere Boston Common Hotel, 200 Stuart Street, Boston, MA, 02116, United States
Major moves in pharma and biotech partnering are reshaping the landscape. For ADC companies, the challenge lies in standing out, validating their offerings, and securing clinical-ready assets amidst this whirlwind of activity.
How does one differentiate and obtain assets poised for clinical success in the next wave of deals?
Enter the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit.
VIEW THE FULL EVENT GUIDE
Why Attend?

Cuts through the noise of partnership events to gather a targeted critical mass of 100+ ADC companies
Provides a platform for networking and fast-tracking the search and evaluation of earlier development assets
Empowers participants to navigate the complex partnering landscape with confidence by significantly improving the alignment, efficiency, and yield of conversations

Secure your place here or get in touch with the team – info@hansonwade.com

Pre-Filled Syringes Connect
2024-09-11 - 2024-09-12 | Boston, USA
SAE Media Group are proud to announce the inaugural Pre-Filled Syringes Connect event taking place on the 11th and 12th of September in Boston. As a new addition to SAE’s leading injectable drug delivery portfolio, PFS Connect will bring together device thought-leaders from big pharma, biotech and device developers in an intimate, relaxed and engaging setting, fostering collaborations and idea exchanges crucial for driving innovation in injectable drug delivery.
The two-day agenda will bring you a series of keynote presentations and roundtable discussions facilitated by industry experts sharing their invaluable expertise and experiences around industry challenges and emerging trends allowing you to come away equipped with actionable knowledge to enhance your device development initiatives and strategic approach. Keynote presentations will also give you the chance gain insight into the latest case studies and innovations in the field. We hope to welcome you to this must attend event in September 2024!
Free to attend for Pharma and Biotechs.

9th CAR-TCR Summit
2024-09-17 - 2024-09-20 | Hynes Convention Center, 900 Boylston St, Boston, MA, 02115, United States
The commercial success of cell therapies is continuing to grow! With a recent TIL approval, a shift to earlier line CAR-T treatment, and further approvals set for this year, 2024 will be pivotal to demonstrate the clinical benefit of cell therapies and advance breakthroughs in solid tumors and autoimmunity.
That’s why now’s the time to join the 9th CAR-TCR Summit: the industry’s definitive forum committed to progressing end-to-end cell therapy development. This year’s 2-day conference will accommodate in-depth tracks covering Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, Analytical Development and Supply Chain & Clinical Operations.
This is your team’s one-stop shop for all functions to discover cutting-edge innovations, significant clinical data and gain insights into how to conquer the bottlenecks withholding optimal durability, accessibility, safety and cost-efficiency.
Join 130+ expert speakers and 1,000+ cell therapy experts to collaborate to achieve the shared goal of delivering these curative treatments to the ever-growing population of patients in need.
To see the speaker faculty, what’s new for 2024, full session details, who you will meet and much more, view the full agenda now: https://ter.li/wjnrky

2nd CRISPR-Based Therapy Analytical Development Summit
2024-09-17 - 2024-09-19 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Develop, characterize, and validate robust analytical tools that demonstrate safety, efficacy, and regulatory compliance of genome editing therapies
As CRISPR-based therapies become ever-complex, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, before finalizing guidance on genome editing therapies in January.
To keep up with these growing analytical demands, the 2nd CRISPR-Based Therapy Analytical Development Summit is returning to unite 50+ key figures across Analytical Development, CMC & QC domains, all with the common goal of developing more precise, accurate, and sensitive analytical assays.
Expert discussions will highlight analytical innovation with both traditional and disruptive CRISPR-based therapies, and span in vivo and ex vivo delivery, covering the following core themes:

Characterization of guides, nucleases, and full drug constructs
Robust non-clinical and CMC assay development, including biodistribution studies, potency assays, and on-/off- target sequencing detection, nomination, and prediction
Meeting regulatory expectations for analytical data to support IND submissions successfully

If you are working to develop, characterize, and validate more robust analytical tools to enable the progression of your early R&D work into a clinical therapy, this is your collaborative forum to equip you with the latest innovation, case studies, and actionable insights to level up your analytical efforts.

3rd mRNA Process Development & Manufacturing Summit
2024-09-17 - 2024-09-19 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
Your Roadmap for mRNA Process Development & Manufacturing with Optimized Purification, Process Analytics & Enhanced Formulation to Improve Cost-Effectiveness & Scalability into the Clinic & Beyond
The mRNA manufacturing industry is experiencing a wave of innovation with the development of cancer vaccines, emerging therapeutics, and novel gene editing tools. Yet, significant challenges remain – largely around the speed, cost of production, and limited flexibility to improve current processes with new technologies.
Returning to Boston this September, the 3rd mRNA Process Development & Manufacturing Summit has been carefully put together to address the industry’s most prominent pain points. Hear from 30+ expert speakers from the likes of BioNTech, Merck & Co., Moderna, Nutcracker Therapeutics, Pfizer, Sanofi, Strand Therapeutics and more across three days of content spanning two tracks dedicated to Research Scale and IND-Enabling & Clinical Scale process development.
Boost your mRNA drug substance to drug product by implementing high throughput process development, optimizing mRNA synthesis and purification, speeding up process analytics and innovating formulation to unlock the unlimited potential of mRNA for all applications.

Dates: September 17-19, 2024
Location: Westin Boston Seaport District, Boston, MA
Event Program: https://ter.li/k46oir

New for 2024, join the mRNA Purification focus day to enhance your upstream and downstream purification processes, or dive into 3 pre-conference workshops to harness high throughput process development technology, master mRNA process changes, drug quality and patient safety, and choose the right external partner.
Download the agenda here: https://ter.li/k46oir
Register your place here (and take advantage of group discounts of up to 20% when sending your team of three or more!): https://ter.li/wf4j0

2nd ADC Process Development Summit
2024-09-17 - 2024-09-19 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
With cutting-edge strategies and industry insights, the 2nd ADC Process Development Summit is back with a mission to boost conjugation yield, optimize purification, and streamline production to meet regulatory standards all whilst minimizing costs and timelines.
Join AstraZeneca, Bristol Myers Squibb, Pfizer and a community of industry experts in process development, conjugation, purification, control, CMC, and engineering. With a focused discussion on process development challenges, innovative solutions and practical takeaways, leave equipped with the technical knowledge and connections to revolutionize your ADC manufacturing process.
This Summit is a must attend for everyone looking to increase conjugation yield and enhance TFF, implement rigorous control strategies for superior drug substance quality, develop scalable processes to cut unit operations, accelerate production timelines, and navigate regulatory landscapes with ease.
Don’t miss this Summit, where innovation meets implementation, ensuring your ADC process development reaches its optimal efficacy and efficiency!

6th RAS-Targeted Drug Development Summit
2024-09-24 - 2024-09-26 | Hilton Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
The race to target the remaining RAS mutants continues, with over 24 clinical and 70 pre-clinical stage programs striving for first- and best-in-class. Now more than ever, we are witnessing this growing industry make strides to utilize novel modalities and elucidate mechanisms of resistance – making treating patients with RAS mutant cancers beyond NSCLC not just a possibility, but a reality.
As the leading industry-centered forum, the 6th RAS-Targeted Drug Development Summit 2024 returns to Boston this September and is once again dedicated to every aspect of discovery and development of RAS therapies, from discovery through to clinical development, to create effective frontline RAS therapies for cancer and better patient outcomes.
Over three jam-packed days, 38+ leading stakeholders will exhibit breakthrough novel data, latest clinical advancements, proof-of-concept, and strategic perspectives, all armed to improve the standard of care for patients in need.
This year’s summit will tackle some of the hottest advances and burning questions in the space, such as:

Targeting more mutants with RAS(ON) form, pan-RAS approaches, and non-canonical targets to combat cancers beyond NSCLC
Defeating intrinsic or acquired mechanistic resistance and reducing off-target effects to ensure more effective RAS-directed medicines reach the patient
Showcasing vaccines, cell therapies, monovalent and heterobifunctional modalities with improved selectivity and potency to avoid cancer recurrence
Investigating valuable combination approaches utilizing inhibitors of up- and downstream high-value targets such as SOS1, MEK, RAF, and ERK

Join 200+ of your biopharma and academic peers from Early Discovery, Translational Oncology, and Clinical Development at the unrivaled end-to-end forum as we foster critical conversations and navigate cutting-edge treatments – empowering the developers of RAS-targeted therapies to make a positive impact on the future of cancer treatment. Join us as we work together to create effective frontline RAS therapies for better patient outcomes.
To know more visit: https://ter.li/hosjv6

AI for Pharma & Healthcare Summit
2024-09-24 - 2024-09-26 | Amsterdam Marriot Hotel, Stadhouderskade 12, Amsterdam, 1054 ES, Netherlands
Join us for an exploration of accelerating drug development, streamlining clinical trials and enhancing supply chain efficiency to elevate patient care across the entire value stream at the AI for Pharma & Healthcare Summit!
Imagine a world where drug discovery moves at unprecedented speeds, clinical trials are streamlined for efficiency, and regulatory approvals are faster than ever before. Extend that vision to manufacturing and supply chain processes enhanced by machine learning and predictive analytics to ensure that treatment reaches patients not only quicker but also more safely and reliably. This is the future of pharmaceuticals, where advanced technology enhances every facet of patient care.
The transformative potential of AI is reflected in the sector’s financial outlook: the market for AI in Pharma is expected to grow exponentially, from $3.05 billion to $18.06 billion by 2029. Yet, amid the excitement, a healthy dose of scepticism about the “AI Hype” exists. Pharma professionals understand the power of the technology, but translating potential into reality requires navigating significant challenges. Pharma IQ’s AI for Pharma & Healthcare Summit aims to address these challenges by going beyond the hype, presenting real-world AI use cases in drug discovery, clinical trials and supply chain / manufacturing.

8th MASH Drug Development Summit
2024-09-24 - 2024-09-26 | Boston Logan Airport Hotel, One Hotel Dr, Boston, MA, 02128, United States
With Rezdiffra’s approval, GLPs moving into the space, and the wave of promising therapeutics in phrase I-III trials, MASH therapeutics have seen an unprecedented boom in recent months.
Don’t miss the 8th MASH Drug Development Summit’s industry-specific curated agenda spanning preclinical, translational, clinical and regulatory MASH developments designed to help you to overcome barriers in the development and commercialization of MASH therapies.
What are the top program features to look forward to in 2024?

Delve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with BMS, Pfizer and AstraZeneca
Accelerate your clinical trial design by optimizing cirrhosis, MASH and fibrosis targets in trials with AstraZeneca and 89Bio
Examine how GLP-1s can be leveraged in MASH to combat the disease drivers with Altimmune and Seal Rock Therapeutics
Explore how the regulatory field is shifting and learn how to navigate regulatory approval with Madrigal and AstraZeneca
Leverage AI techniques and real-world evidence to integrate data, harmonize predictions and identify future trends for MASH with Merck and AstraZeneca

Find out more here.
This is a conversation you won’t want to miss! Discover pricing and registation information here to discover how you can harness competitive intelligence from 3 days of cutting-edge content to supercharge your MASH therapeutic pipeline.

6th Macrophage-Directed Therapies Summit
2024-10-01 - 2024-10-03 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
Learning From the Past & Spearheading Macrophage Clinical Acceleration
The 6th Macrophage-Directed Therapies Summit is uniting 60+ biopharma and academia leaders across R&D, Discovery, Biology, Translational, and Clinical Development fields for invaluable networking and insights into all facets of macrophage-directed therapies.
Grab your Full Agenda – https://ter.li/nqf2qd
Despite toxicity concerns for CD47 targets in 2023, the macrophage community persists in exploring innovative targets. Their determination to unveil new data showcasing safety and proof of concept remains stronger than ever, revitalizing momentum in this highly promising industry.
This October, you could meet leading experts from Verseau Therapeutics, Inceptor Bio, Carisma Therapeutics, Elpiscience Biopharmaceuticals, John Hopkins School of Medicine, Resolution Therapeutics, and more, offering exclusive insights into their winning strategies for staying ahead of the curve in the years ahead.
Key Highlights:

Tackling challenges in delivery, administration, animal model selection, reprogramming, manufacturing, and more to optimize choices
Exploring indications for extending beyond oncology to autoimmunity, inflammation, neurodegenerative diseases, and beyond
Assessing the evolving macrophage-therapeutics landscape to uncover innovative targets and the latest data

Register Here for the Best Savings – https://ter.li/o22pxt

4th iPSC Drug Development & Manufacturing Summit
2024-10-01 - 2024-10-03 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment. Introducing the 4th iPSC Drug Development & Manufacturing Summit, your longest standing and definitive iPSC focused platform.
No iPSC stone will be left unturned, as key industry experts including Kenai Therapeutics, Cytovia Therapeutics, Aspen Neuroscience, NIST and many more, unite under one roof to transform the future of iPSC cell therapies. For the first time in 4 years, uniting R&D teams, manufacturing experts and business leaders, across 2 tracks of content for 3-days of cutting edge data presentations and strategic cross-functional discussions. Take a look at the full session details today.
With all this and more, don’t miss this golden opportunity to help you and your entire team stay at the forefront of the iPSC cell therapy revolution!

Wearable Injectors and Connected Devices UK
2024-10-14 - 2024-10-15 | London, UK
SAE Media Group’s 5th Annual Wearable Injectors and Connected Devices Conference will explore on-body device design and development whilst also engaging in the latest advances in connectivity and digital health applications for wearable devices with industry perspectives from big pharma representatives. The conference will consider key developments in the wearable injectors field, including the enhanced demand for on-body injectors and digitalised health as the need for at home self-administration and routes for delivery of time-dependent, high volume and viscous drugs grow.

The conference will also cover key regulatory updates such as guidance on MDR requirements from regulatory and notified bodies, and the importance of considering user-experience and developing patient-centric devices. The two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity, and a platform for exchanging ideas.
Why attend:

2 full days of networking opportunities.
16+ sessions with 75% of speakers from big pharma companies.
An agenda designed for professionals within the injectables space, focused on the development, implementation and application of wearable injectors and connected devices.
The only conference discussing wearable injectors and connected devices together, other than our USA version of this event.

The Experience:

A collaborative environment for pharma, biotech and device developers to discuss the latest trends and challenges within the wearable injectors and connected device market.
Learn from key industry players about new technologies, strategies and processes for the development of wearable injectors.
Gain insights into the regulatory processes for the approval of wearable injectors and develop a greater understanding of how-to bring devices to market.
Create a dialogue with industry leaders and develop a network with the key stakeholders in the market.
Delve into the world of digital health for the healthcare sector and discuss implementation of connectivity with on-body drug delivery systems.
Examine the importance of usability for at home injectors, and what is needed to make a device appropriate for patient administration.

Reuters Events: Pharma & Patient USA 2024
2024-10-15 - 2024-10-16 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
Are you listening to your patient community? It’s not enough. Standing in the shadows and harvesting anecdotal insights won’t build connections, create first-hand knowledge or illuminate your impact to internal stakeholders.

We must step forward and be visible, actively engaging in patient communities and embedding the patient voice internally. YOU are the patient advocate in your company, so overturn tokenistic gestures into meaningful actions that prioritise patients over patents.
This starts now. You must integrate and co-create from the outset, from clinical design to commercial execution to boost adherence, trial participation and create exceptional outcomes. Show that pharma is driven by more than profit – to build a world that empowers all patients and leaves no one in the dark. THIS is the real value of your work.
Welcome to Pharma & Patient USA, the co-created event for patient champions in pharma, who won’t sit back. This October you will engage with leading pharma executives and patient advocates to learn first-hand how to drive change that will build a brighter and more inclusive future in healthcare.
Are you ready to be the new beacon of trust? Join us to be in the room, be visible and be engaged.

6th Annual TIL Therapies Summit
2024-10-22 - 2024-10-24 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Following the watershed approval of Iovance’s Lifileucel, all eyes are now on TIL therapies as the up-and-coming major therapeutic avenue for solid tumor treatment. Introducing the 6th Annual TIL Therapies Summit! With 30+ expert speakers, 12 new speaker companies, 2 brand-new content-filled tracks and 2 brand-new interactive workshops, you won’t want to miss out!
Hear from TIL industry leaders like Iovance, MD Anderson Cancer Center, Obsidian Therapeutics, Steven Rosenberg’s group from the National Institute of Health and more, as they share ground-breaking TIL discoveries from R&D to commercialization.
Join us in October to capitalize on this golden opportunity to ensure you and your entire team stay ahead of the TIL wave!

5th CFC Summit
2024-10-22 - 2024-10-24 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 5th Commercializing Flow Chemistry Summit marks a pivotal year, introducing a significant shift in content to address the evolving needs of the pharmaceutical manufacturing industry. This summit zeroes in on advanced scale-up capabilities and stakeholder engagement strategies, responding to a market that is rapidly expanding and forecasted to reach US $4.6 billion by 2032. Attendees will delve into specialized sessions that focus on late–stage process development, enhanced regulatory compliance, and innovative manufacturing techniques like electrochemistry and continuous processing.
This event is crucial for professionals aiming to stay ahead in an industry moving towards more sustainable and efficient production methods. With a fresh emphasis on practical, application-focused content, the summit provides essential insights and networking opportunities, making it a must-attend event for those looking to drive technical and strategic decision-making in their organizations.
To know more visit: https://ter.li/wiczxd
